EP
PCVX icon

Eversept Partners’s Vaxcyte PCVX Stock Holding History

Eversept Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.6M Sell
629,952
-294,241
-32% -$16M 1.9% 15
2026
Q1 		$53.7M Sell
924,193
-273,529
-23% -$14.8M 2.83% 10
2025
Q4 		$55.3M Sell
1,197,722
-224,261
-16% -$10M 2.78% 9
2025
Q3 		$51.2M Buy
1,421,983
+123,469
+10% +$4.09M 3.53% 7
2025
Q2 		$42.2M Buy
1,298,514
+741,444
+133% +$24.3M 3.88% 6
2025
Q1 		$21M Buy
557,070
+429,482
+337% +$34.3M 2.14% 15
2024
Q4 		$10.4M Buy
+127,588
New +$12.7M 0.93% 26
2024
Q3 		– Sell
-96,089
Closed -$7.26M – 79
2024
Q2 		$7.26M Sell
96,089
-101,242
-51% -$6.89M 0.5% 36
2024
Q1 		$13.5M Sell
197,331
-36,508
-16% -$2.53M 0.9% 22
2023
Q4 		$14.7M Buy
233,839
+43,409
+23% +$2.25M 1.29% 19
2023
Q3 		$9.71M Sell
190,430
-5,261
-3% -$260K 0.82% 24
2023
Q2 		$9.77M Sell
195,691
-103,359
-35% -$4.9M 0.82% 28
2023
Q1 		$11.2M Buy
299,050
+120,597
+68% +$5.12M 0.78% 27
2022
Q4 		$8.56M Buy
+178,453
New +$7M 0.75% 30

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Eversept Partners's PCVX Position: Q2 2026 in Review

Eversept Partners reduced its Vaxcyte (PCVX) stake by 32% in Q2 2026, selling an estimated $16M and leaving 629,952 shares worth $36.6M. The position accounts for 1.9% of the portfolio, ranked #15.

Eversept Partners first reported a position in PCVX in Q4 2022 and has held it in 14 quarters since. The position peaked at $55.3M in Q4 2025. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Eversept Partners held 629,952 shares of Vaxcyte worth $36.6M as of Q2 2026.
  • Eversept Partners sold 294,241 Vaxcyte shares in Q2 2026, an estimated $16M.
  • Vaxcyte made up 1.9% of Eversept Partners's portfolio in Q2 2026, its #15 holding.
  • Eversept Partners first reported a position in Vaxcyte in Q4 2022 and has held it in 14 quarters since.
  • Eversept Partners's Vaxcyte position peaked at $55.3M in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.